Elche

• Phase 3, Open-label Study of ARV-471 (PF-07850327) vs Fulvestrant in Participants With ER(+)/ HER2(-) Advanced Breast Cancer (VERITAC-2) Recruiting
  2022-500544-38-00 5 2023-06-05 Advanced Breast Cancer
• A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or … Recruiting
  2025-523461-17-01 5 2026-06-01 LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER
• Multicenter clinical trial on the effectiveness and safety of outpatient treatment of acute uncomplicated diverticulitis without antibiotics … Recruiting
  2025-523121-17-00 6 2026-05-29 Diverticular disease of the intestine,
• A Randomized, Placebo-controlled, Parallel Phase 2a Dose-ranging Study to Investigate the Efficacy, Safety, and Tolerability of Topical HT-0 … Recruiting
  2025-523058-16-00 4 2026-04-28 Skin Toxicities Associated with Epidermal Growth Factor Receptor Inhib
• A clinical study of islatravir and ulonivirine for people with HIV-1 who have not been treated before (MK-8591B-062) Recruiting
  2025-522519-40-00 10 2026-03-16 HIV
• Beamion LUNG-3: A study to test whether zongertinib helps people with surgically removed, non-small cell lung cancer with HER2 mutations com … Recruiting
  2025-521284-12-00 5 2026-03-05 Non-small cell lung cancer
• An Open-Label Extension, Multi-Centered, Phase 2 Trial of TEV-56286 (Emrusolmin) for Multiple System Atrophy Recruiting
  2025-521642-14-00 4 2026-03-05 Multiple System Atrophy
• A Study in Adults with Parkinson's Disease and a Lack of Interest or Motivation to Test How Different Doses of IRL757 Given for Multiple Day … Recruiting
  2025-523612-37-00 3 2026-01-23 Parkinson's Disease and Apathy
• A Study to Compare the Efficacy and Safety of Prasinezumab with a placebo in Participants with Early-Stage Parkinson’s Disease Recruiting
  2025-522683-32-00 5 2026-01-15 Early-Stage Parkinson’s Disease (PD)
• A proof of concept study to evaluate treatments´efficacy by monitoring Minimal Residual Disease using ctDNA in HR-positive/HER2-negative ear … Recruiting
  2023-505661-89-00 4 2025-12-19 Early-stage, Hormone Receptor (HR)-positive / Human Epidermal Growth F
• Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Subjects With Primary Membranous Nephropathy Recruiting
  2025-521661-27-00 10 2025-12-19 Primary Membranous Nephropathy
• Phase II study of tarlatamab as a follow-up treatment after chemo and radiation in patients with small cell lung cancer (SCLC) who cannot re … Recruiting
  2024-515201-26-00 4 2025-12-09 Small cell lung cancer (SCLC)
• Phase III clinical trial to evaluate the efficacy and safety of specific immunotherapy with mannanconjugated allergoids for the treatment of … Recruiting
  2023-508548-23-00 5 2025-11-21 Aetiological treatment of moderate-to-severe allergic rhinitis/rhinoco
• Study of Izalontamab Brengitecan (BMS-986507) versus Treatment of Physician’s Choice in Patients with Previously Untreated, Locally Advanced … Recruiting
  2024-519871-24-00 10 2025-11-11 Breast cancer
• A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated with Alzheimer’s Disease. Recruiting
  2025-520613-31-00 5 2025-10-31 Agitation Associated with Alzheimer’s Disease
• A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esoph … Recruiting
  2023-509630-19-00 5 2025-07-31 Esophageal Squamous Cell Carcinoma (ESCC)
• A Study to Assess safety and Effectiveness of the Inavolisib Plus a CDK4/6 Inhibitor and Letrozole Versus Placebo Plus a CDK4/6 Inhibitor an … Recruiting
  2024-516162-11-00 5 2025-07-14 Endocrine-Sensitive phosphatidylinositol 3-kinase (PIK3CA)-Mutated, Ho
• Study of the treatment of patients with non-small cell lung cancer with metastasis with Cemiplimab and subsequent treatment with Cemiplimab … Recruiting
  2024-518812-38-00 4 2025-07-02 Non-small cell lung cancer (NSCLC)
• A clinical study to assess the safety and efficacy of oral ART0380 as a single agent or in combination in solid tumors Recruiting
  2024-511534-12-00 7 2025-06-10 Advanced or Metastatic Solid Tumours
• Trial of Trastuzumab Deruxtecan (Enhertu®) Plus Chemotherapy Plus or Minus Pembrolizumab versus Chemotherapy Plus Trastuzumab Plus or Minus … Recruiting
  2024-513122-27-00 5 2025-06-10 Unresectable, Locally Advanced or Metastatic HER2 positive Gastric or
• A Worldwide Study Testing the New Drug Olverembatinib for Patients with Chronic Phase Chronic Myeloid Leukemia (POLARIS-2) Recruiting
  2024-511495-32-00 5 2025-04-16 Chronic Phase Chronic Myeloid Leukemia
• A phase II study assessing safety and efficacy of REPotrectinib in ROS1-positive non-small cell lung cancer patients with active brain mEtas … Recruiting
  2023-508112-35-00 4 2025-04-15 ROS1-positive non-small cell lung cancer (NSCLC) with active brain met
• PRESERVE-003: ONC-392 (Study Drug) Versus Docetaxel (Standard of Care) in Metastatic Non-small Cell Lung Cancer That Progressed on PD-1/PD-L … Recruiting
  2023-505311-20-01 5 2025-03-21 Metastatic Non-Small Cell Lung Cancer
• Clinical trial of molnupiravir (MK-4482) in adults who have COVID-19 and are not hospitalized, who are at high risk for serious illness from … Recruiting
  2023-507227-36-00 5 2025-02-21 SARS-CoV-2 (COVID-19) infection

Showing 25–48 of 129 trials